The revolutionary healthcare cloud-based IT company reputed for considerable progress in converging science and technology through a single consolidated clinical platform, NantHealth, has announced that Celgene Corp. has pledged to a strategic $25 million investment in the firm, furthering the ongoing partnership between the two companies.
Celgene made an investment of $75 million in NantBioScience, a member of the NantWorks group of companies, earlier in 2014.
The latest investment is aimed to leverage NantHealth's established and acclaimed knowledge base and clinical operating system (cOS) to further help clinicians and medical researchers in creating unique and proven new approaches to detect, prevent, diagnose and treat cancer.
Dr. Patrick Soon-Shiong, founder and CEO of NantHealth, stated : "Our mission our commitment is to empower clinicians with 21st-century clinical decision support in real time, at the first point of care, through the power of supercomputing, genomic analysis and molecular analysis. We are proud that Celegene has joined us in advancing this commitment; one which requires providers and researchers to work in close collaboration to innovate and then deliver molecular-designed cancer treatments for patients, ensuring they receive the right care at the right time to positively and proactively alter the course of their disease. We are in discussions with multiple pharmaceutical companies to collaborate with NantHealth in the development of personalized medicines where the power of one, informs many."
CFO, and new president, Hematology & Oncology of Celgene, Jacqualyn Fouse, added : "Celgene is excited to invest once again in Dr. Soon-Shiong s vision and proven ability to deliver molecularly driven personalized medicine. We believe it is crucial for pharmaceutical companies to collaborate with and invest in visionary and groundbreaking companies like NantHealth and NantBioScience to both advance the development of new drugs and to help the millions of patients in need."